What development phase is VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E in?

VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E is FDA-approved (marketed).

Last reviewed 2026-05-13 · How we verify

VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E

FDA-approved approved Vaccine component Quality 0/100

At a glance

Generic name	VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E
Modality	Vaccine component
Phase	FDA-approved
First approval	2018

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E CI brief — competitive landscape report
VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E updates RSS · CI watch RSS